

Jie-Lena Sun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4528006/publications.pdf>

Version: 2024-02-01

18
papers

356
citations

933447

10
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

828
citing authors

#	ARTICLE	IF	CITATIONS
1	The Cost-Effectiveness of Palliative Care: Insights from the PAL-HF Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 662-669.	1.7	8
2	Outcomes of Endovascular Therapy in Patients With Prestroke Mobility Impairment. <i>Stroke</i> , 2021, 52, e725-e728.	2.0	0
3	Performance of Guideline Recommendations for Prevention of Myocardial Infarction in Young Adults. <i>Journal of the American College of Cardiology</i> , 2020, 76, 653-664.	2.8	39
4	Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006758.	3.9	8
5	Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT). <i>American Journal of Cardiology</i> , 2019, 123, 1193-1201.	1.6	7
6	Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. <i>Clinical Cardiology</i> , 2018, 41, 945-952.	1.8	22
7	Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial. <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000523.	2.8	32
8	Updated risk factors should be used to predict development of diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 859-863.	2.3	5
9	Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 145-153.	2.1	18
10	Implications of Serum Chloride Homeostasis in Acute Heart Failure (from ROSE-AHF). <i>American Journal of Cardiology</i> , 2017, 119, 78-83.	1.6	44
11	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	15
12	Association of standard clinical and laboratory variables with red blood cell distribution width. <i>American Heart Journal</i> , 2016, 174, 22-28.	2.7	10
13	Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2015, 8, 1044-1051.	3.9	52
14	Venous Thromboembolism and Cardiovascular Risk: Results from the NAVIGATOR Trial. <i>American Journal of Medicine</i> , 2015, 128, 297-302.	1.5	9
15	Chronic obstructive pulmonary disease and cardiovascular risk: Insights from the NAVIGATOR trial. <i>International Journal of Cardiology</i> , 2014, 176, 1126-1128.	1.7	11
16	Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 554-561.	3.4	37
17	A Novel Risk Classification Paradigm for Patients With Impaired Glucose Tolerance and High Cardiovascular Risk. <i>American Journal of Cardiology</i> , 2013, 112, 231-237.	1.6	5
18	Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease Study. <i>American Heart Journal</i> , 2010, 160, 371-379.e2.	2.7	33